Jennifer K. Richer - Concepedia

Author

Jennifer K. Richer

University of Colorado Anschutz Medical Campus ORCID

Also Known As

J K Richer, J. K. Richer, J. Richer, J.K. Richer, JENNIFER RICHER, Jennifer K Richer, Jennifer K. Richer, Jennifer Richer, Kathryn Saraf, Richer, Jennifer K.

502

Publications

9.7K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Anschutz Medical Campus University of Colorado Denver University of Colorado Health University of Colorado Cancer Center University of Pittsburgh

About

Jennifer K. Richer is an author at University of Colorado Anschutz Medical Campus specializing in medicine, cell biology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	42	3.5K
2	Natural Sciences	4	4	95
3	Health Sciences	3	3	215
4	Engineering	2	2	226
5	Biochemistry	2	2	146

Jennifer K. Richer

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells Jennifer K. Richer, Britta M. Jacobsen, Nicole Manning, Journal of Biological Chemistry	2002	570
The Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding Coactivator L7/SPA and the Corepressors N-CoR or SMRT Twila A. Jackson, Jennifer K. Richer, David L. Bain, Molecular Endocrinology Corepressors N-corSteroid Receptor AntagonistsPharmacotherapyYeast CellsSteroid Metabolism	1997	464
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide Dawn R. Cochrane, Sebastián Bernales, Britta M. Jacobsen, Breast Cancer Research	2014	391
Progesterone Regulates Transcription of the p21 Cyclindependent Kinase Inhibitor Gene through Sp1 and CBP/p300 Gareth I. Owen, Jennifer K. Richer, Lin Tung, Journal of Biological Chemistry	1998	350
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents Dawn R. Cochrane, Nicole S. Spoelstra, Erin N. Howe, Molecular Cancer Therapeutics	2009	312
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer Nicholas C. D’Amato, Thomas J. Rogers, Melita A. Gordon, Cancer Research Breast OncologyCell DeathCancer BiologyMammary Gland DevelopmentTumor Biology	2015	293
Targets of miR-200c mediate suppression of cell motility and anoikis resistance Erin N. Howe, Dawn R. Cochrane, Jennifer K. Richer Breast Cancer Research	2011	256
Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i> Valerie N. Barton, Nicholas C. D’Amato, Melita A. Gordon, Molecular Cancer Therapeutics Androgen ReceptorBreast OncologyCancer BiologyTumor BiologyOncology	2015	211
Convergence of Progesterone and Epidermal Growth Factor Signaling in Breast Cancer Carol A. Lange, Jennifer K. Richer, Tianjie Shen, Journal of Biological Chemistry	1998	200
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors Diana M. Cittelly, Partha Das, Nicole S. Spoelstra, Molecular Cancer	2010	186

Page 1